APA (7th ed.) Citation

Weisel, K., Dimopoulos, M. A., Beksac, M., Leleu, X., Richter, J., Heeg, B., . . . Mikhael, J. (2024). Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: An indirect treatment comparison. Leukemia & Lymphoma, 65(4), 481. https://doi.org/10.1080/10428194.2023.2300051

Chicago Style (17th ed.) Citation

Weisel, Katja, et al. "Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs. Lenalidomide-sparing Pomalidomide-containing Triplet Regimens for Relapsed/refractory Multiple Myeloma: An Indirect Treatment Comparison." Leukemia & Lymphoma 65, no. 4 (2024): 481. https://doi.org/10.1080/10428194.2023.2300051.

MLA (9th ed.) Citation

Weisel, Katja, et al. "Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs. Lenalidomide-sparing Pomalidomide-containing Triplet Regimens for Relapsed/refractory Multiple Myeloma: An Indirect Treatment Comparison." Leukemia & Lymphoma, vol. 65, no. 4, 2024, p. 481, https://doi.org/10.1080/10428194.2023.2300051.